Motley Fool highlights AbbVie and Johnson & Johnson as dividend stabilisers amid Middle East tensions

On 19 July 2026, The Motley Fool published an analysis recommending AbbVie and Johnson & Johnson as key holdings for investors seeking stability amid escalating tensions in the Middle East. The financial services firm identified both companies as "Dividend Kings," a classification reserved for firms that have increased their dividend payouts for at least 50 consecutive years. The recommendation was framed as a strategy to protect portfolios against broader equity volatility and potential market disruptions stemming from geopolitical conflict.

AbbVie was highlighted for its robust immunology portfolio, specifically the drugs Skyrizi and Rinvoq, which the analysis noted are outperforming management expectations. The firm pointed to the company’s investigational weight-loss medicine, ABBV-295, as a potential differentiator in the anti-obesity market due to its monthly administration schedule, contrasting it with weekly competitors. Additionally, AbbVie’s recent acquisition of Apogee Therapeutics and its eczema candidate zumilokibart was cited as evidence of a deepening pipeline. The analysis attributed a 54-year streak of dividend increases to AbbVie, noting a forward yield of 2.8 per cent.

Johnson & Johnson was recommended for its diversified healthcare business, which spans pharmaceuticals and medical devices across immunology, oncology, and neuroscience. The Motley Fool emphasised the company’s track record of launching new products to navigate patent cliffs and regulatory pressures. A key focus was the company’s pursuit of regulatory clearance for Ottava, a robotic-assisted surgery device intended to enter the underpenetrated surgical robotics market. The analysis cited a 64-year history of dividend growth for Johnson & Johnson, with a forward yield of 2.1 per cent.

The article included historical performance data from The Motley Fool’s Stock Advisor service to illustrate the potential of long-term equity holdings. It claimed that a $1,000 investment in Netflix at the time of its 2004 recommendation would have grown to $371,842 by 19 July 2026, while a similar investment in Nvidia, recommended in 2005, would have reached $1,244,783. The service reported a total average return of 900 per cent over the period, compared to 207 per cent for the S&P 500.

Both companies were presented as defensive assets capable of sustaining income for investors regardless of economic conditions. The Motley Fool noted that AbbVie’s products remain in high demand due to their therapeutic necessity, while Johnson & Johnson’s diversified structure provides resilience against recessions and pandemics. The publication concluded that both stocks offer consistent dividend growth, making them suitable for income-seeking investors navigating current market uncertainties.